JP3638338B2 - Melanin production inhibitor - Google Patents

Melanin production inhibitor Download PDF

Info

Publication number
JP3638338B2
JP3638338B2 JP14853895A JP14853895A JP3638338B2 JP 3638338 B2 JP3638338 B2 JP 3638338B2 JP 14853895 A JP14853895 A JP 14853895A JP 14853895 A JP14853895 A JP 14853895A JP 3638338 B2 JP3638338 B2 JP 3638338B2
Authority
JP
Japan
Prior art keywords
extract
melanin production
kippi
production inhibitor
whitening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP14853895A
Other languages
Japanese (ja)
Other versions
JPH08337534A (en
Inventor
論 橋爪
美和 大月
博伸 鴨田
Original Assignee
株式会社アドバンストスキンリサーチ研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社アドバンストスキンリサーチ研究所 filed Critical 株式会社アドバンストスキンリサーチ研究所
Priority to JP14853895A priority Critical patent/JP3638338B2/en
Publication of JPH08337534A publication Critical patent/JPH08337534A/en
Application granted granted Critical
Publication of JP3638338B2 publication Critical patent/JP3638338B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【0001】
【産業上の利用分野】
本発明は、生薬であるキッピ( 橘皮) の抽出エキスを有効成分として含有するメラニン生成抑制剤に関する。メラニン生成抑制剤は、美白化粧料、皮膚老化防止剤、等として有用である。
【0002】
【従来の技術】
皮膚の老化現象の1 つにシミ・ソバカスの色素沈着が在る。その成因は、未だ完全に解明されてはいないが、その成因の1 つは、太陽光等からの紫外線がメラニンを産生するメラノサイトを活性化し、それによりメラニンが過剰に産生されることであると考えられている。このような観点から、シミ・ソバカスの治療剤又は防止剤として、紫外線吸収剤の他に、アスコルビン酸やハイドロキノン誘導体等の還元剤、コウジ酸やリノール酸等のチロシナーゼ阻害剤( 例えば、特開昭63-284109 号公報、特開平1-85907 号公報を参照のこと。) 、カテコール配糖体等を主成分とする美白剤( 例えば、特開平4-1115号公報を参照のこと。) 、フラボノイドを主成分とする美白剤( 例えば、特開昭55-92305号公報を参照のこと。) 、イソフエルラ酸を主成分とする美白剤( 例えば、特開昭62-10312号公報を参照のこと。) 、アゼライン酸を主成分とする美白剤( 例えば、特開昭61-85307号公報を参照のこと。) 、等が開発されてきた。
一方、キッピ( 橘皮) は、日本においては、ウンシュウミカンその他の近縁植物の、中国においては、福橘(Citrus tangerina Hort. et Tanaka)、朱橘(C. erythrosa Tanaka) 、等( ミカン科) の、成熟した果皮を乾燥したものであり、別名、陳皮ともいわれるものである。これは、d-リモネンを主成分とする精油、ヘスペリジンのほか、ペクチン、クエン酸、等を含む。これは、芳香性健胃、鎮嘔、鎮咳、去痰薬として、消化不良、胃炎、はきけ、しゃっくり、感冒、等に用いられる。これは、漢方においては、二陳湯、香蘇散、杏蘇散、平胃散、釣藤散、等に配合されて使用されることが知られている( 天然薬物辞典 奥田拓男 編 廣川書店) 。しかしながら、キッピの抽出エキスがメラニン産生抑制作用をもつこと、そしてこれを有効成分として含有せしめて美白剤を作り出すことは、現在、当業者に知られていない。
【0003】
【発明が解決しようとする課題】
先に列挙した従来技術の美白剤は、いずれもその効果が不十分であり、シミ・ソバカスの予防及び治療に対する市場の関心が非常に高まってきた今日においては、より強いメラニン産生抑制作用をもつ美白剤の開発が望まれている。
従って、本発明の目的は、より強いメラニン産生抑制作用をもつメラニン生成抑制剤を提供することである。
【0004】
【課題を解決するための手段】
本発明者らは、前記の課題を解決することができるメラニン生成抑制物質の探索を続けた結果、キッピの抽出エキスが顕著なメラニン産生抑制作用をもつ化合物であることを発見し、本発明を完成するに至った。
すなわち、本発明に従って、生薬であるキッピ抽出エキスを有効成分として含んで成るメラニン生成抑制剤を提供する。
本発明に係るメラニン生成抑制剤は、日焼けによるシミ・ソバカス、色黒、等の発生並びに色素沈着症を予防及び治療することを目的とした皮膚外用剤の形態で、使用されることもできる。
本発明に係るキッピ抽出エキスとは、a)乾燥後粉砕した30〜150gのキッピに、1 リッターのエタノールを加え、70℃に加熱し、そして還流しながら3 時間、温浸したエタノール抽出物; b)乾燥後粉砕した30〜150gのキッピに、1 リッターのエタノール/ 水混合溶媒を加え、時々攪拌しながら室温〜50℃において浸漬した後、圧搾分離して得た抽出物; c)乾燥後粉砕した30〜150gのキッピに、1 リッターのメタノールを加え、70℃に加熱し、そして還流しながら3 時間、温浸したメタノール抽出物; d)ジエチルエーテル、アセトン、酢酸エチル、ヘキサン、等による抽出物、等をいう。
場合により、このように調製した抽出エキスの濃度を調整する目的でその抽出溶媒をエバポレーターによりさらに留去させて、その濃度を高めたもの又は粉末化したものをそのまま製剤に混合することもできる。
【0005】
本発明に係るメラニン生成抑制剤を適用する場合、キッピ抽出エキスの配合量は、特に制限されないが、その皮膚外用剤の全重量当たり、抽出エキスの乾燥重量として、好ましくは0.0001〜1 重量% 、より好ましくは0.005 〜0.1 重量% であることができる。この配合量が0.0001重量% 未満である場合、色素沈着症の予防又は治療の目的を十分に達成することができないことがあり、また、その配合量が1 重量% を超える場合、以下に述べるような剤形に調製する際に、溶解性、分散性、等の点でその調製が困難になる恐れがある。
本発明に係るメラニン生成抑制剤を、公知の方法で軟膏剤、クリーム、乳液、パック剤、化粧水、等の剤形に調製することができる。また、これらの剤形の調製において使用することができる構成成分の種類、配合量、等は、慣用例に従って当業者により適宜決定されることができる。これらの構成成分の種類、配合量、等は、以下の実施例により限定されるべきではなく、その目的の剤形を調製し得ることが知られている任意の種類、配合量、等であることができる。尚、これらの皮膚外用剤、薬剤、等の調製において、慣用のメラニン生成抑制剤、紫外線吸収剤、紫外線散乱剤、抗炎症剤、等を合わせて配合してもよい。
【0006】
【実施例】
以下の実施例によって本発明をさらに説明するが、本発明の範囲は、これらの実施例により限定されてはならない。
【0007】
実施例 1 並びに比較例 1 及び 2
まず、本発明に係るメラニン生成抑制剤の成分であるキッピの抽出エキスのメラニン産生抑制作用に対する効果を評価する実験の結果を示す。
キッピを株式会社 金井藤吉商店( 東京都千代田区鍛冶町1-9-11) から入手した。このキッピは、中国産であり、ミカン科タチバナ(Citrus tachibana Tanaka Citrus)の果実が原料であり、10月以降成熟した果実を採り、果皮を陰干し若しくは日干ししたものであった。30g のキッピに、240ml のエタノールを加え、70℃に加熱し、そして還流しながら3 時間、温浸してエタノール抽出液を得て、これを抽出エキスとして使用した。
HM3KO 細胞白色化効果
細胞白色化効果の評価実験に使用した細胞は、ヒト皮膚由来のメラノーマ細胞系HM3KO である。この細胞系は、従来この種の実験において多用されてきたマウス由来のB16 メラノーマ細胞系と同様に、通常の条件下でその細胞内にメラニンを多く産生する性質を有し、本試験に使用する細胞として適するものである。また、本実験においてヒト皮膚由来の細胞系を使用することは、人体への応用を考慮した薬物評価法として、より適当であることができる。
HM3KO 細胞を直径10cmの培養皿内に1 x 105 個/ 皿の密度で蒔き、そしてウシ胎児血清を10% 含むダルベッコ変法イーグル培地を使用して37℃において24時間培養した。その後、キッピ抽出エキスをその培地中濃度が( 抽出エキス乾燥重量として)0.0001 〜0.01% となるように添加し、そして6 日間培養した。培養後、その細胞を回収し、遠心分離により細胞ペレットを作り、そしてその色調を、肉眼観察により以下の4 段階評価法:
+++ : 顕著な白色化を認める
++ : 十分な白色化を認める
+ : 僅かな白色化を認める
± : 白色化を認めない
において白色化度を測定することにより評価した。
【0008】
一方、比較例1 及び2 としてメラニン産生抑制作用有することが知られているハイドロキノン・モノベンジル・エーテル( 特開昭61-227516 号公報を参照のこと。) とコウジ酸( 特開昭63-2770619号公報を参照のこと。) をそれぞれ使用して実施例1 と比較した。結果を表1 中に示す。
【0009】

Figure 0003638338
表1 中から見られるように、キッピ抽出エキスは、ハイドロキノン・モノベンジル・エーテル及びコウジ酸よりも強い白色化作用を有している。
【0010】
実施例 2 及び比較例 3
PUVA 処置により有色モルモット A-1 において誘導される色素沈着の抑制試験
キッピ抽出エキスがインビトロにおいて培養細胞(HM3KO) の白色化作用を示すことは前述の通りであるが、さらに実験動物を使用したインビボにおける試験においても同様の作用を示すか否かを調べるために、次のような試験を行った。
本試験に使用した有色モルモットA-1 は、English 系の有色モルモットJY-8とハートレー系アルビノ・モルモットとの交配種であり、シナモン色の被毛をもち、紫外線により色素沈着を誘導されることができる。48週齢の雄性のA-1 の背部被毛をバリカンとシェーバーにより剃毛した後、その背部に色素沈着を起こさせる部位を2 x 2 cmの正方形に区切って設けた。この部位に、30ppm の8-メトキシソラーレン(8-Methoxypsoralen) 50μl を塗布後、30分間放置し、そしてその部位に長波長紫外線UV-Aを、10J/cm2 のエネルギー量において照射した。照射直後からその試験部位に0.5%キッピ抽出エキスのエタノール溶液100 μl を塗布し、その後この塗布を1 日2 回の頻度で40日間連続して行い、そしてその色素沈着の程度を、ACI ジャパンのTIASによるデンシトメトリー解析を用いて、エタノールだけを塗布した対照と比較した。その結果、キッピ抽出エキスを塗布した部位が、対照に比較して、明らかに色素沈着の程度が軽減されていたことが、観察された。
【0011】
以下の表2 中に、色素沈着の程度を、色素沈着が弱い順に[1] 〜[5] の5 段階の等級により評価した結果を示す。皮膚の明度は、使用した動物の個体間での差異があるため、明度の絶対値による評価を行わずに、動物個体毎に相対的に評価した。ここで、
等級[1] は、色素沈着が誘導されていない、すなわち、紫外線が照射されていない皮膚の明度(A1 ) を指し、
等級[5] は、薬剤を全く塗布されずに紫外線が照射された色素沈着の度合いが最も大きい皮膚の明度(A5 ) を指し、そして
等級[2] 〜[4] は、それぞれ、上記等級[1] の明度と等級[5] の明度との差を3 段階に内分する明度(A2 〜A 4 ) を指す。すなわち
A 2 = A 1 + (A 5 - A 1 ) × 1/4
= A + (A − A ) × 2/4
A 4 = A 1 + (A 5 - A 1 ) × 3/4
である。
【0012】
また、本試験においては、キッピ抽出エキスを塗布した部位に、副作用、例えば、炎症性の過敏反応の発生、例えば、紅斑の発生、は、見られず、それ故、キッピ抽出エキスが副作用を呈さない範囲内で有効にメラニンの生成を抑制することができることを確認した。
Figure 0003638338
【0013】
以下の実施例3 〜7 において、本発明に係るメラニン生成抑制剤の配合の例を挙げる。
Figure 0003638338
A に属する成分を湯浴上で溶かし( 油相) 、そして別にB に属する成分を加熱溶解する( 水相) 。得られた油相に水相を添加し、攪拌して乳化させ、そして冷却して、軟膏剤1 を得た。
【0014】
Figure 0003638338
A に属する成分を湯浴上で溶かし( 油相) 、そして別にB に属する成分を加熱溶解する( 水相) 。得られた油相に水相を添加し、攪拌して乳化させ、そして冷却して、軟膏剤2 を得た。
【0015】
Figure 0003638338
上記配合物群A 及びB を70℃においてそれぞれ溶かし、そしてB にA を添加し、そして均一に乳化させて、乳液とした。
【0016】
Figure 0003638338
上記の各成分を均一に溶かしてパック剤を得た。
【0017】
Figure 0003638338
精製水に、グリセリン、1,3-ブチレングリコール、ヒアルロン酸ナトリウム、エデト酸2 ナトリウム、クエン酸ナトリウム、塩化アンモニウム及びL-アスコルビン酸燐酸エステル・マグネシウムを溶解して、水溶液を得た。一方、別にエタノール、キッピ抽出エキス及びポリオキシエチレン・オレイル・エーテル(20E.O.)を混合した。この混合物を上記水溶液に添加し、溶解し、そして濾過して、化粧水を得た。
【0018】
【発明の効果】
これまで説明してきたように、本発明は、新規且つ有効なメラニン生成抑制剤を提供することができ、そしてこれらを配合した化粧料は、優れた美白効果と、日焼け等によるシミ・ソバカスの予防及び治療効果を有し、且つ安全性の高いものである。[0001]
[Industrial application fields]
The present invention relates to a melanin production inhibitor containing, as an active ingredient, an extract of kippi (tachibana peel) which is a crude drug. The melanin production inhibitor is useful as a whitening cosmetic, a skin aging inhibitor, and the like.
[0002]
[Prior art]
One of the skin aging phenomena is pigmentation of spots and freckles. The cause has not yet been fully elucidated, but one of the causes is that ultraviolet rays from sunlight etc. activate melanocytes that produce melanin, thereby producing excessive melanin. It is considered. From such a point of view, as a treatment or inhibitor for stains and freckles, in addition to ultraviolet absorbers, reducing agents such as ascorbic acid and hydroquinone derivatives, tyrosinase inhibitors such as kojic acid and linoleic acid (for example, JP 63-284109 and JP-A-1-85907), whitening agents mainly composed of catechol glycosides (for example, see JP-A-4-115), flavonoids Whitening agent (for example, see JP-A-55-92305), whitening agent containing isoferulic acid as a main component (for example, see JP-A-62-10312). ), Whitening agents based on azelaic acid (see, for example, JP-A-61-85307), and the like have been developed.
On the other hand, Kippi (Tachibana bark) is one of the other related plants in Japan, such as Citrus tangerina Hort. Et Tanaka, C. erythrosa Tanaka, etc. ) Of the dried pericarp, also known as the crust. This includes pectin, citric acid, etc., in addition to essential oils and hesperidin based on d-limonene. It is used as an aromatic healthy stomach, sedation, antitussive, expectorant, indigestion, gastritis, rash, hiccup, cold, etc. In Chinese medicine, it is known that it is used in combination with Nichichento, Kososan, Kyososan, Hirakusansan, Choitosan, etc. (Takuo Okuda, edited by Takuo Okuda, Yodogawa Shoten) . However, it is not currently known to those skilled in the art that the extract of Kippi has a melanin production-inhibiting action and that it contains this as an active ingredient to produce a whitening agent.
[0003]
[Problems to be solved by the invention]
All of the prior art whitening agents listed above have insufficient effects, and have a stronger melanin production-suppressing effect in the present day when the market interest in prevention and treatment of stains and freckles has increased greatly. Development of a whitening agent is desired.
Accordingly, an object of the present invention is to provide a melanin production inhibitor having a stronger melanin production inhibitory action.
[0004]
[Means for Solving the Problems]
As a result of continuing the search for a melanin production inhibitor capable of solving the above-mentioned problems, the present inventors have found that the extract of Kippi is a compound having a remarkable melanin production inhibitory effect, and It came to be completed.
That is, according to the present invention, there is provided a melanin production inhibitor comprising, as an active ingredient, a kippi extract, which is a crude drug.
The melanin production inhibitor according to the present invention can also be used in the form of an external preparation for the purpose of preventing and treating the occurrence of spots, freckles, dark black, etc. and pigmentation caused by sunburn.
The kippi extract according to the present invention is a) ethanol extract obtained by adding 1 liter of ethanol to 30-150 g of kippi dried and ground, heated to 70 ° C., and digested for 3 hours while refluxing; b) An extract obtained by adding 1 liter of ethanol / water mixed solvent to 30-150 g of the milled powder after drying and immersing at room temperature to 50 ° C. with occasional stirring, followed by pressing and separating; c) after drying Add 1 liter of methanol to 30-150 g of crushed chippi, heat to 70 ° C. and digest for 3 hours at reflux; d) with diethyl ether, acetone, ethyl acetate, hexane, etc. An extract, etc.
In some cases, for the purpose of adjusting the concentration of the extracted extract thus prepared, the extraction solvent can be further distilled off by an evaporator, and the concentrated or powdered product can be directly mixed with the preparation.
[0005]
In the case of applying the melanin production inhibitor according to the present invention, the amount of the Kippi extract extract is not particularly limited, but is preferably 0.0001 to 1% by weight as the dry weight of the extract extract based on the total weight of the skin external preparation. More preferably, it can be 0.005 to 0.1% by weight. If the amount is less than 0.0001% by weight, the objective of preventing or treating pigmentation may not be fully achieved, and if the amount exceeds 1% by weight, When preparing a new dosage form, the preparation may be difficult in terms of solubility, dispersibility, and the like.
The melanin production inhibitor according to the present invention can be prepared into dosage forms such as ointments, creams, emulsions, packs, and lotions by a known method. Moreover, the kind of component which can be used in preparation of these dosage forms, a compounding quantity, etc. can be suitably determined by those skilled in the art according to a common example. The types, blending amounts, etc. of these components should not be limited by the following examples, but are any types, blending amounts, etc. that are known to be able to prepare the intended dosage form. be able to. In the preparation of these external preparations for skin, drugs, etc., a conventional melanin production inhibitor, ultraviolet absorber, ultraviolet scattering agent, anti-inflammatory agent, etc. may be combined.
[0006]
【Example】
The following examples further illustrate the invention, but the scope of the invention should not be limited by these examples.
[0007]
Example 1 and Comparative Examples 1 and 2
First, the result of the experiment which evaluates the effect with respect to the melanin production inhibitory effect of the extract of a Kippi which is a component of the melanin production inhibitor which concerns on this invention is shown.
Kippi was obtained from Kanai Tokichi Shoten Co., Ltd. (1-9-11 Kajicho, Chiyoda-ku, Tokyo). This Kippi was made in China and was made from the fruits of the Citrus tachibana Tanaka Citrus. The fruits were matured from October and the skin was shaded or sun-dried. To 30 g of the pipe, 240 ml of ethanol was added, heated to 70 ° C., and digested with reflux for 3 hours to obtain an ethanol extract, which was used as an extract.
HM3KO cell whitening effect The cells used for the cell whitening effect evaluation experiment are human skin-derived melanoma cell line HM3KO. This cell line, like the mouse-derived B16 melanoma cell line that has been used extensively in this type of experiment, has the property of producing a large amount of melanin in the cell under normal conditions and is used in this test It is suitable as a cell. In addition, the use of human skin-derived cell lines in this experiment can be more appropriate as a drug evaluation method considering application to the human body.
HM3KO cells were seeded at a density of 1 × 10 5 cells / dish in a 10 cm diameter culture dish and cultured at 37 ° C. for 24 hours using Dulbecco's modified Eagle medium containing 10% fetal calf serum. Thereafter, the Kippi extract was added so that its concentration in the medium (as the dry weight of the extract) was 0.0001 to 0.01%, and cultured for 6 days. After incubation, the cells are collected, a cell pellet is made by centrifugation, and the color is evaluated by visual observation in the following four-step evaluation method:
+++: Remarkable whitening was recognized ++: Sufficient whitening was recognized +: Slight whitening was observed ±: Evaluation was made by measuring the degree of whitening without whitening.
[0008]
On the other hand, as Comparative Examples 1 and 2, hydroquinone monobenzyl ether (see Japanese Patent Application Laid-Open No. 61-227516) and kojic acid (Japanese Patent Application Laid-Open No. 63-2770619), which are known to have an inhibitory action on melanin production. Each of which was used for comparison with Example 1. The results are shown in Table 1.
[0009]
Figure 0003638338
As can be seen from Table 1, the Kippi extract has a stronger whitening effect than hydroquinone monobenzyl ether and kojic acid.
[0010]
Example 2 and Comparative Example 3
Inhibition test of pigmentation induced in colored guinea pig A-1 by treatment with PUVA As described above, the extract of Kippi shows the whitening action of cultured cells (HM3KO) in vitro. In order to examine whether or not the same effect is exhibited in an in vivo test using the following, the following test was conducted.
The colored guinea pig A-1 used in this study is a hybrid of the English colored guinea pig JY-8 and the Hartley albino guinea pig, which has cinnamon-colored hair and is induced to induce pigmentation by ultraviolet rays. Can do. A 48-week-old male A-1 back coat was shaved with a clipper and a shaver, and then a site for causing pigmentation on the back was divided into 2 × 2 cm squares. This site was coated with 50 μl of 30 ppm 8-methoxypsoralen, allowed to stand for 30 minutes, and then irradiated with long-wavelength ultraviolet UV-A at an energy level of 10 J / cm 2 . Immediately after irradiation, 100 μl of 0.5% Kippi extract extract ethanol solution was applied to the test site, then this application was performed twice a day for 40 consecutive days, and the degree of pigmentation was determined by ACI Japan. Densitometric analysis by TIAS was used to compare with a control applied with ethanol alone. As a result, it was observed that the site where the Kippi extract was applied was clearly reduced in the degree of pigmentation compared to the control.
[0011]
Table 2 below shows the results of evaluation of the degree of pigmentation by the five grades [1] to [5] in order of increasing pigmentation. Since the brightness of the skin varies among individuals of the animals used, the evaluation was made relative to each individual animal without performing evaluation based on the absolute value of the brightness. here,
Grade [1] refers to the lightness (A 1 ) of the skin where pigmentation is not induced, that is, not irradiated with ultraviolet light,
Grade [5] refers to the lightness (A 5 ) of the skin with the highest degree of pigmentation that was irradiated with ultraviolet rays without any drug applied, and grades [2] to [4] are the above grades, respectively. The lightness (A 2 to A 4 ) that divides the difference between the lightness of [1] and the lightness of grade [5] into three levels. Ie
A 2 = A 1 + (A 5 -A 1 ) × 1/4
A 3 = A 1 + (A 5 −A 1 ) × 2/4
A 4 = A 1 + (A 5 -A 1 ) × 3/4
It is.
[0012]
Also, in this test, no side effects such as the occurrence of inflammatory hypersensitivity reactions such as erythema were observed at the site where the Kippi extract was applied, and therefore the Kippi extract exhibited side effects. It was confirmed that the production of melanin can be effectively suppressed within a range not present.
Figure 0003638338
[0013]
In the following Examples 3 to 7, examples of blending the melanin production inhibitor according to the present invention will be given.
Figure 0003638338
Ingredients belonging to A are dissolved in a hot water bath (oil phase), and components belonging to B are dissolved by heating (aqueous phase). An aqueous phase was added to the obtained oil phase, and the mixture was stirred to emulsify and cooled to obtain an ointment 1.
[0014]
Figure 0003638338
Ingredients belonging to A are dissolved in a hot water bath (oil phase), and components belonging to B are dissolved by heating (aqueous phase). An aqueous phase was added to the obtained oil phase, and the mixture was stirred to emulsify and cooled to obtain an ointment 2.
[0015]
Figure 0003638338
The above blend groups A and B were each melted at 70 ° C., and A was added to B and uniformly emulsified to give an emulsion.
[0016]
Figure 0003638338
Each of the above components was uniformly dissolved to obtain a pack agent.
[0017]
Figure 0003638338
In purified water, glycerin, 1,3-butylene glycol, sodium hyaluronate, disodium edetate, sodium citrate, ammonium chloride and L-ascorbic acid phosphate / magnesium were dissolved to obtain an aqueous solution. Separately, ethanol, Kippi extract and polyoxyethylene oleyl ether (20E.O.) were mixed. This mixture was added to the aqueous solution, dissolved and filtered to obtain a lotion.
[0018]
【The invention's effect】
As described so far, the present invention can provide a novel and effective melanin production inhibitor, and a cosmetic containing these has excellent whitening effect and prevention of spots and freckles due to sunburn and the like. And has a therapeutic effect and is highly safe.

Claims (2)

キッピ(橘皮)の抽出エキスを有効成分として含有するメラニン生成抑制剤。  Melanin production inhibitor containing an extract of kippi (tachibana peel) as an active ingredient. 皮膚外用剤の形態にある、請求項1に記載のメラニン生成抑制剤。  The melanin production inhibitor of Claim 1 which exists in the form of a skin external preparation.
JP14853895A 1995-06-15 1995-06-15 Melanin production inhibitor Expired - Lifetime JP3638338B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14853895A JP3638338B2 (en) 1995-06-15 1995-06-15 Melanin production inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14853895A JP3638338B2 (en) 1995-06-15 1995-06-15 Melanin production inhibitor

Publications (2)

Publication Number Publication Date
JPH08337534A JPH08337534A (en) 1996-12-24
JP3638338B2 true JP3638338B2 (en) 2005-04-13

Family

ID=15455023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14853895A Expired - Lifetime JP3638338B2 (en) 1995-06-15 1995-06-15 Melanin production inhibitor

Country Status (1)

Country Link
JP (1) JP3638338B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916576A (en) * 1997-05-30 1999-06-29 Amway Corporation Method of scavenging free radicals using orange extract
JP3993936B2 (en) * 1998-05-22 2007-10-17 一丸ファルコス株式会社 Melanin production inhibitor and cosmetic composition
JP4992164B2 (en) * 2000-04-19 2012-08-08 日油株式会社 Cosmetic composition
JP4524935B2 (en) * 2001-02-16 2010-08-18 日油株式会社 Whitening cosmetics
JP2006225359A (en) * 2005-02-21 2006-08-31 Kanebo Cosmetics Inc Bleaching cosmetic

Also Published As

Publication number Publication date
JPH08337534A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
EP1049451B1 (en) Use of compounds for protecting skin from uv induced immunosuppression
CN108498413B (en) Cosmetic composition containing whitening compound
US9403042B2 (en) Composition for treatment of skin
JP2012502020A (en) Cosmetic composition comprising polyhydroxylate (POLYHYDROXYLTATE) fatty alcohol and derivatives and uses thereof
KR101230277B1 (en) Composition of External Application for Using Bamboo Sprout
JP3638338B2 (en) Melanin production inhibitor
JP2000319155A (en) Matrix metalloprotease inhibitor, and aging preventive lotion containing the same
JPH04346911A (en) Cosmetic
JP2004175734A (en) Dermopathy inhibitor, dermopathy-improving agent, and skin care preparation for external use containing them
JPH08337510A (en) Melanin formation inhibitor
KR20140008364A (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
JP2005350412A (en) Nerve growth factor production inhibitor, and skin care preparation for external use, cosmetic, quasi-medicine, itching-preventing and treating agent, and atopic dermatitis medicine which contain the nerve growth factor production inhibitor
KR20150025680A (en) EXTERNAL APPLICATING COMPOITION COMPRISING OF PPARΑ/γ DUAL ACTIVATOR FOR INHIBITING AND IMPROVING OF SKIN AGING
JPH10158148A (en) Skin-whitening cosmetic
JP2001114636A (en) Hyaluronic acid production and catalase production promoting agent, fibroblast activating agent and skin lotion
US20220401379A1 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
WO2011126189A1 (en) Composition for preventing hair loss and stimulating hair growth
US20150104426A1 (en) Skin-care agent containing pleurotus ferulae fruit body extract or pleurotus ferulae mycelium extract
JP3585288B2 (en) Melanin production inhibitor
JP2708692B2 (en) Whitening cosmetics
JP2001114637A (en) Hyaluronic acid production promoting agent and skin lotion containing the agent
JP4129475B2 (en) Collagen synthesis promoter and skin external preparation composition containing the same
JPH08337528A (en) Suppressant for melanogenesis
JP2003335656A (en) Skin care preparation for external use
KR20210009526A (en) A skin-care agent containing hyaluronic acid complex

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040706

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040819

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041012

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050111

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100121

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120121

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130121

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130121

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140121

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term